Diana Zuckerman


Diana M. Zuckerman is an American health policy analyst who focuses on the implications of policies for public health and patients’ health. She is an expert on national health policy, particularly in women's health and the safety and effectiveness of medical products. She is the President of the National Center for Health Research and the Cancer Prevention and Treatment Fund.

Early life and education

Zuckerman earned her B.A. in psychology from Smith College and then obtained a Ph.D in psychology from The Ohio State University in 1977. At Yale Medical School she was a post-doctoral fellow in epidemiology and public health from 1979 to 1980.

Career

She was on the faculty at Vassar College and Yale University, and directed a longitudinal study of college students as director of the Seven College Study at Harvard University, publishing books and articles on the impact of media on children, the impact of religion on the health of the elderly, and how women's life experiences influence their mental and physical health. She left academia in 1983 when she was selected as a Fellow in the American Association for the Advancement of Science Congressional Science Fellowship program.
From 1985 to 1993 she worked at the U.S. Congress in a House subcommittee where she was responsible for a dozen Congressional oversight investigations on health and social policy, including political manipulation of government grants to prevent child abuse, lack of safeguards for infertility treatments, financial conflicts of interest among National Institutes of Health grant recipients, and the lack of safety studies on breast implants. Information from the hearings received widespread public health, government, and media attention, resulting in several policy and regulatory changes, including the U.S. Food and Drug Administration requiring implant manufacturers to submit safety studies for the first time.
In 1993, Zuckerman joined the staff of the Senate Veterans Affairs Committee and began an investigation that resulted in the first Congressional hearings focused on the possible causes of Gulf War syndrome. In 1995 she was a senior policy advisor in the Clinton Administration. From 1996, she undertook leading roles in non-profit organizations, including, from 1999, presidency of the National Research Center for Women & Families and The Cancer Prevention and Treatment Fund.
Her work focuses on improving the quality of medical products and healthcare in the United States. She has been highly critical of scientific and medical research paid for by companies, who then use this to promote their products, as well as the lack of media coverage on independently funded research that challenges industry-funded research. She has said:
In February 2011, Zuckerman and colleagues Paul Brown and Dr. Steven Nissen published a study in the peer-reviewed journal Archives of Internal Medicine, which evaluated the FDA's recalls of devices that the agency considered potentially deadly or otherwise very high risk. Based on FDA data, the authors determined that most of the devices that were high-risk recalls had never been studied in clinical trials prior to FDA approval, and that the FDA needed to use more stringent criteria for implanted medical devices and those used to diagnose serious illnesses, and an editorial in the same issue agreed.
In April 2011, Zuckerman presented the results of the study at a hearing by the U.S. Senate Special Committee on Aging.
Zuckerman is the author of five books, several book chapters, and dozens of articles in medical and academic journals, and in newspapers across the country. Her policy work has resulted in news coverage on all the major TV networks, including ABC, CBS, NBC, CNN, Fox News, public television, 60 Minutes, 20/20, National Public Radio, and in major U.S. print media such as The New York Times, The Washington Post, The Washington Times, Los Angeles Times, Boston Globe, USA Today, Detroit Free Press, New York Daily News, Newsweek, Time, U.S. News and World Report, Family Circle, The New Yorker, Glamour, Self, as well as many other newspapers, magazines, and radio programs.

Testimonies

Zuckerman has appeared before numerous FDA advisory committees to testify as a medical expert on a variety of drugs and devices.
On December 12, 2013, Zuckerman testified regarding the type-2 diabetes drug dapagliflozin, saying: "My concern about this drug is that there are just too many unanswered questions – and those unanswered questions are frightening ones. That was true when the FDA rejected this application for approval 2 years ago, and it is still true today." She cited studies that highlighted the risks that the drug poses, as well as methodological concerns such as a lack of diversity in clinical trials.
On November 14, 2012, Zuckerman made a statement at a Capitol Hill press conference about the VALID Compounding Act. She stated that loopholes in the FDA law, including compounding pharmacies, have allowed hundreds of people to get sick with meningitis and several to die. The VALID Compounding Act is designed to close the loopholes that are so harmful to patients.
Dr. Zuckerman spoke at the FDA Opioid Policy Steering Committee on January 30, 2018, recommending better data and improved resources for the safe disposal of unused opioid medications. Additionally, she suggested requiring more effective Risk Evaluation and Mitigation Strategy training for physicians that prescribe opioids as part of that presentation and as an invited speaker at the National Academies of Sciences, Engineering, and Medicine in 2016.
In 2017 and 2018, she testified about the risks of artificial turf used on playing fields and playgrounds before government hearings of legislative committees of the state of Maryland and District of Columbia, as well as before the federal Consumer Product Safety Commission. Dr. Zuckerman urged that natural grass be used instead of artificial turf and that engineered wood fiber be used instead of artificial rubber playgrounds.

Awards

Zuckerman frequently writes articles regarding medical drugs and devices, as well as public health policy. Recent articles published in peer-reviewed journals include:
*